Rubraca (rucaparib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Rubraca (rucaparib), covering 2022-02-09 to 2022-02-09. Get the full timeline:
Most recent: Clinical Trial Update: An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]